Vanguard Portfolio Management
PRCT icon

Vanguard Portfolio Management’s Procept Biorobotics PRCT Stock Holding History

Vanguard Portfolio Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.1M Buy
2,526,802
+105,440
+4% +$2.64M ﹤0.01% 1682
2026
Q1 		$60.6M Buy
+2,421,362
New +$68.2M ﹤0.01% 1613

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management's PRCT Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Procept Biorobotics (PRCT) stake by 4.4% in Q2 2026, buying an estimated $2.64M and bringing the position to 2,526,802 shares worth $57.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1682.

Vanguard Portfolio Management first reported a position in PRCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $60.6M in Q1 2026. 253 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Vanguard Portfolio Management held 2,526,802 shares of Procept Biorobotics worth $57.1M as of Q2 2026.
  • Vanguard Portfolio Management bought 105,440 Procept Biorobotics shares in Q2 2026, an estimated $2.64M.
  • Procept Biorobotics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1682 holding.
  • Vanguard Portfolio Management first reported a position in Procept Biorobotics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's Procept Biorobotics position peaked at $60.6M in Q1 2026.
  • 253 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.